3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
35
Breast Neoplasms
34
Lung Neoplasms
20
Triple Negative Breast Neoplasms
6
Neoplasm Metastasis
5
Adenocarcinoma of Lung
5
Uterine Cervical Neoplasms
4
Rhabdomyosarcoma
3
Neoplasms
3
NSCLC
3
Hodgkin Disease
3
Rhabdomyosarcoma, Embryonal
2
Rhabdomyosarcoma, Alveolar
2
Recurrence
2
Adenocarcinoma
2
Thoracic Neoplasms
1
Sarcoma
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Non - Small Cell Lung Cancer NSCLC
1
Neuralgia
1
Metastatic HER2-positive Breast Cancer
1
Mesothelioma, Malignant
1
Malignant mesenchymal tumor
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Lung Diseases
1
HR+HER2- Breast Cancer
1
HER2-positive Advanced Breast Cancer
1
Interventions
Carboplatin
17
Cisplatin
14
Paclitaxel
12
Pemetrexed
11
pembrolizumab
9
Gemcitabine
7
Docetaxel
6
Sorafenib
5
osimertinib
4
durvalumab
4
130-nm albumin-bound paclitaxel
4
padeliporfin
3
cabozantinib
3
atezolizumab
3
Taxes
3
Radiotherapy
3
Mitomycin
3
Magnetic Resonance Spectroscopy
3
Cetuximab
3
Bevacizumab
3
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
3
trifluridine tipiracil drug combination
2
regorafenib
2
olaparib
2
Sunitinib
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Nivolumab
2
Irinotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Carcinoma
×
Vinorelbine
×
Clear all
NCT02915744
2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3
Completed
178 enrolled
37 charts